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A B S T R A C T   
The COVID-19 pandemic is challenging how healthcare technologies are evaluated, as new, more dynamic 
methods are required to test the cost effectiveness of alternative interventions during use rather than before 
initial adoption. Currently, health technology assessment (HTA) tends to be static and a priori: alternatives are 
compared before launch, and little evaluation occurs after implementation. We suggest a method that builds 
upon the current pre-launch HTA procedures by conceptualizing a mean-variance approach to the continuous 
evaluation of attainable portfolios of interventions in health systems. Our framework uses frontier analysis to 
identify the desirability of available health interventions so decision makers can choose diverse portfolios based 
upon information about expected returns and risks. This approach facilitates the extension of existing methods 
and assessments beyond the traditional concern with pre-adoption data, a much-needed innovation given the 
challenges posed by COVID-19.   
1. Introduction 
The coronavirus 2019 (COVID-19) pandemic will have unprece-
dented health, economic, and social consequences globally (Fernandes, 
2020). The current crisis is severely challenging resource-limited health 
systems worldwide with demands for novel interventions and extra ca-
pacity, and the economic slowdown caused by country-wide lockdowns 
and other measures is diminishing the ability to fund future service 
provision (Emanuel et al., 2020; Legido-Quigley et al., 2020). Globally, 
COVID-19 is testing the ability of countries to quickly develop, test, and 
deploy new medications, with serious concerns being raised about the 
processes for evaluating and approving drugs (Rome and Avorn, 2020). 
Given the role of health economics in assessing the cost effectiveness of 
available interventions, COVID-19 will also create challenges for the 
health technology assessment (HTA) of innovative treatments 
(Mukherjee, 2021). 
As an applied discipline, health economics has evolved rapidly over 
recent decades, with notable advances in the development of evalua-
tion techniques (Paulden, 2020). Accompanying this growth has been 
the increasing use of economic methods in the evaluation of health 
technologies by bodies such as the UK’s National Institute for Health 
and Care Excellence (NICE) and the Institute for Clinical and Economic 
Review in America (Thokala et al., 2020). The growing use of economic 
methods in applied evaluations has led to the continual modification of 
techniques originally recommended by authorities such as the U.S. 
Panel on Cost-Effectiveness (Gold, 1996). For instance, best practice 
originally recommended the use of the cost-effectiveness ratio, which 
was soon replaced by the Incremental Cost Effectiveness Ratio (ICER) 
accompanied by the Cost Effectiveness Acceptability Curve (CEAC). 
Recently, the modelling of Net Health Benefits has been recommended. 
Approaches that summarize uncertainty in cost-effectiveness analysis 
using these methods focus only on uncertainty associated with costs 
and effects of programs under consideration. In the real world, most 
decision-makers have to fund a portfolio of health care programs. 
Therefore, a more comprehensive approach would analyze the uncer-
tainty of costs and effects of all programs supported by fixed healthcare 
budgets (Sendi et al., 2003). In response, we suggest a novel method for 
supporting health systems decision-makers, which uses real world data 
to analyze the uncertainty and cost-effectiveness of portfolios of 
available interventions. 
Portfolio theory has an established pedigree as an approach for 
establishing the efficiency of new health care investments; in particular, 
Birch and Donaldson proposed integer programming as a method for 
selecting between mutually exclusive projects (Birch and Donaldson, 
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1987). Similarly, the mean-variance approach central to portfolio theory 
has been included in several papers, with Sendi, Gafni and Birch sug-
gesting analysing uncertainty in cost-effectiveness analysis by intro-
ducing a new graphical framework (the “decision making plane”) for 
communicating with policy makers about the opportunity costs related 
to their decisions (Sendi et al., 2002). The authors later extended this 
approach to the context of a portfolio of programs when costs and effects 
are uncertain and resources are constrained (Sendi et al., 2003). Gafni, 
Walter and Birch develop the literature further by illustrating how a 
decision-making plane may be used to explicitly incorporate opportu-
nity costs into healthcare decision-making, as well as relaxing the as-
sumptions of perfect divisibility and constant returns to scale of the 
cost-effectiveness plane (Gafni et al., 2013). Our approach builds upon 
the work of these authors but attempts to add to the literature by sug-
gesting adjustments to portfolio analysis that may make the method 
more popular to analysts and health systems decision-makers. In 
particular, we suggest that the concept of “technical change”, which is a 
commonly used framework in mainstream economics, should be adop-
ted by health economists during their HTA work (Elster, 1983). 
Akehurst et al. (2017) suggest that all HTA evaluations generally 
follow five distinct phases: horizon scanning, topic determination, evi-
dence collection and assessment, appraisal, and funding and policy 
determination. However, the economic evidence currently collected and 
assessed during these stages is “static” in that only current technologies 
(and the costs of their associated working practices and means of pro-
duction) are compared. Even if future costs and benefits are modelled 
and factor prices are altered, the submitted economic evidence rarely 
captures the evolving dynamics of technical change. Indeed, a major 
limitation of current mainstream HTA work is the inability of its static 
procedures to analyze continuous economic costs and benefits through 
time. 
The purpose of this paper is to present a framework for conceptu-
alizing a mean-variance approach to the continuous evaluation of 
attainable portfolios of health interventions. The proposed framework is 
developed using frontier analysis to represent the evolving efficiency of 
health technologies while in use. The validity of using frontier analysis 
has been widely established, with robust examples from both HTA 
(Bradford et al., 2001; Caro et al., 2010) and the measurement of health 
systems efficiency (Hollingsworth, 2008; Alonso et al., 2015; Sun et al., 
2017; Baines, 2018a). 
We base our work on the method of representing expected values and 
uncertainty developed within modern portfolio theory (MPT) as shown 
in Markowitz (1952). We believe that a modified version of the 
“mean-variance analysis” performed in MPT can successfully form the 
basis of what we call “portfolio frontier analysis” (PFA), which we 
present here as a novel application of MPT for use in economic decision 
making in continually disturbed health systems. 
PFA could make a significant contribution to both research and 
practice, with a clear potential to generate measurable improvements in 
health systems performance worldwide. The framework is designed to 
appeal to a broad interdisciplinary and international readership by 
avoiding the mathematical treatment of risk and pay-offs found in the 
finance literature. The approach has relevance for research in health 
systems and health economics, as well as management science and 
public health. As health systems in all countries (regardless of their 
structure and public/private mix) can influence the cost effectiveness of 
interventions supplied to patients, PFA is applicable internationally and 
the concept is transferrable to all health settings. 
To demonstrate the potential of the PFA approach, this paper pro-
ceeds as follows: Section 1.1 discusses static health technology assess-
ment; Sections 1.2 and 1.3 outline how data and modelling may be 
combined with expert opinion to construct beliefs about the future 
performance of selected health techniques. Sections 1.4 to 1.6 lay out 
the PFA framework and its relation to MPT as a way of representing the 
expected returns and uncertainties of individual health technologies, 
while Sections 1.7 and 1.8 discusses the usefulness of the PFA approach 
as a form of post-adoption HTA process and how it could support health 
system decision-making worldwide. Section 2 concludes. 
2. HTA and the static approach 
An issue underlying all current approaches to HTA assessment is the 
use of static projections of dynamic processes. While the health eco-
nomics literature has attempted to overcome this issue by better 
modelling of uncertainty, especially in a Bayesian framework (Briggs 
et al., 1994), there is a manifest need for insights from mainstream 
economics to better integrate dynamism into evaluation models. A 
salient example comes from macroeconomics and the approach of Salter 
(1960), who considers the limitations of using static equilibrium con-
cepts to analyze continuous economic processes and suggests a dynamic 
alternative. He reports that techniques of production change over time 
for two reasons: improving technical knowledge and changing factor 
prices. These are ongoing processes that together create continuous 
streams of new working methods. Because of this process, Salter argues 
that “once-over” analysis using comparative statics is only appropriate 
to changes in techniques that are sufficiently great to totally displace all 
pre-existing methods. For instance, the replacement of the typewriter by 
the personal computer would have been worth evaluating within a static 
framework because typewriter technology came to an end as a viable 
form of production with this innovation. 
By applying Salter’s reasoning, new health technologies should not 
be evaluated using once-over analysis unless the new technology is 
sufficiently disruptive (this is important because data from clinical trials 
and results from pre-adoption modelling rarely capture the cumulative 
benefits slowly delivered by improving technical knowledge and 
changing factor prices). On the other hand, Salter (1960) argues that the 
cumulative benefits of small unnoticed modifications and improvements 
in production methods or adaptation of existing technologies may be 
equally as great as the significant changes created by discrete large-scale 
innovations. This dynamic may improve health system efficiency by 
increasing benefits and controlling rising costs through reallocation of 
resources, recognizing the actual changes occurring in factor prices. 
Indeed, the slow but continuous change of factor prices is often sufficient 
to produce a constant stream of new techniques of production with 
significant economic benefits. For example, with no intervention for 
COVID-19 available, health systems may find that operational im-
provements may initially stem from thousands of small changes in 
working practices rather than from large gains from a “blockbuster” 
vaccine. 
Any technology may be evaluated post-launch. However, Fig. 1 
suggests that technologies in the first and third quadrants of the cost- 
effectiveness plane may be particularly good candidates for post- 
adoption analysis because their economic profiles may change over 
time. Indeed, HTA bodies cannot know, a priori, how the process of 
(what Salter calls) “continuous disturbance” will affect the discounted 
net value of technologies over time. Long-term patient flows may be 
represented in Markov modelling or budget impact analysis, but the 
dynamics of constant technical change are much harder to predict and 
capture. Consequently, post-adoption economic analysis may be 
required. Moreover, guidelines that recommend the universal adoption 
of new technologies soon after a positive HTA assessment may “crowd- 
out” the slow process of change that may have occurred otherwise. For 
instance, the requirement that the UK National Health Service must fully 
implement NICE guidance within three months may affect the ways in 
which knowledge generation and price modifications occur, particularly 
for novel interventions. As these options suggest, PFA may be used on all 
technologies post-launch, and HTA bodies must decide policies that 
determine their approach to this type of continuous evaluation. 
The PFA offers an important methodological development for HTA, 
particularly during the COVID-19 pandemic. The approach is important 
because it shifts the emphasis from static, pre-launch evaluation to the 
dynamic analysis of interventions in use. Doing so, the approach moves 
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attention from efficacy to effectiveness, and takes advantage of the 
growing availability of real-world data (RWD). At present, there is no 
“gold standard” for using post-launch RWD for evaluating the relative 
cost-effectiveness of healthcare interventions (Makady et al., 2017). PFA 
could become the method of choice for using real world evaluation in 
HTA work. 
To date, portfolio approaches to HTA may have failed to gain 
popularity because of a lack of robust theoretical support. Economic 
evaluations in health care are usually supported by welfarist and extra- 
welfarist theoretical frameworks (Brouwer et al., 2008). In contrast, 
Salter’s approach to conceptual approach to technical change offers a 
new theoretical foundation for HTA, which employs methods to capture 
dynamic gains accrued during use. As an example, many small changes 
to dietary advice, the use of statins and vitamins, better guidelines for 
obesity care and diabetes, combined, may be more cost-effective in “at 
risk” patient groups at preventing COVID-19 related deaths than 
vaccination. Therefore, we believe that applying mean-variance analysis 
to HTA for health systems under pressure may benefit both 
decision-makers and patients. 
3. Shifting the curve: incorporating a portfolio approach 
Salter’s analytical framework is based upon the concept of “best- 
practice techniques” (BPTs), which he defines as the methods that yield 
“minimum costs in terms of the production function and relative factor 
prices of each date.” (Salter, 1960) (p.23) In economic terms, we could 
say that BPTs create outputs located on the boundary of an efficiency 
frontier, with less productive methods creating outputs located inside, at 
a distance from what could be achieved by being like the best. 
3.1. Mean-variance analysis 
Given the importance of BPTs in evaluating efficiency in continually 
disturbed economic systems, we adopt this approach in our framework 
but operationalize Salter’s concept specifically in the context of 
healthcare. We focus on employing the data generated, tested, and/or 
verified by health economists on the post-adoption evaluation of health 
technologies so that the measurement of their economic value and un-
derstanding of uncertainty becomes an ongoing process. 
To explain how these existing methods of data generation and evi-
dence verification may be applied differently, we propose using the 
seminal work on modern portfolio theory by Markowitz (1952). His key 
insight is that expected returns should not be evaluated in isolation but 
should be simultaneously assessed alongside their associated risks. To do 
this, Markowitz suggests “mean-variance analysis” as a way of repre-
senting investment portfolios in terms of expected risks and returns. In 
this theory, the rate of returns (r) on assets are random variables of 
which the first two moments (i.e., expected value and variance) are used 
to obtain the optimal weighted portfolio. This theory can be analytically 






















where P represents the number of assets constructing a portfolio, wi is 
the weight representing the investment proportion for the ith asset (i =
1, …,P), σij indicates the covariance between the ith and jth assets, μi =
E(ri) is the expected value of the rate of return from asset i, and μb is the 
target baseline expected rate of return. 
Markowitz’s framework has significant similarities to the processes 
usually used for HTA. For instance, both measure “discounted expected 
returns” to establish the efficiency of investments or spending. Similarly, 
both use a form of “variance of return” to represent the reliability of 
deterministic estimates of discounted investment yields or cost- 
effectiveness calculations. Markowitz (1999) reports that the standard 
deviation is the most intuitively meaningful measure of dispersion in 
investment portfolios. 
Our framework modifies Markowitz’s work on finance for use in HTA 
and health systems. However, Markowitz focuses on formal financial 
markets that usually have lower and upper limits on the rate of returns 
and risks acceptable to investors. In health systems, minimum levels of 
expected cost effectiveness and maximum degrees of uncertainty are not 
institutionalized in the same way. The absence of these limits makes 
Markowitz’s model harder to employ in a health systems context. In 
response, we address this problem by introducing the notion of an 
“economic floor” and an “uncertainty ceiling” into our framework. 
A key feature of Markowitz’s work is the way he links risk-free in-
vestments with an efficient frontier to create his “capital market line”. 
We modify his approach to introduce a similar decision-making frontier 
into PFA and innovate the practical application of MPT by representing 
the dynamic movements of health technologies within the payoff- 
uncertainty space. 
A brief example of the problem of estimating technological effec-
tiveness under uncertainty and, more importantly, volatility, is shown in 
Fig. 2 where rate of return (r) is a variable that, in repeated sampling, 
will provide different numerical estimates that may be represented 
diagrammatically as a probability distribution. As r is not constant, 
healthcare purchasers will face uncertainty in the rate of returns they 
can accrue from the interventions they purchase. This is shown in the 
diagram where interventions one, two and three all have the same 
dispersion in r (shown by similar normal distribution curves), even 
though they have differing expected values. In contrast, intervention 
four has a much larger return but is accompanied by greater uncertainty 
because r is more variable around its expected value. As this example 
Fig. 1. Cost effectiveness plane for post adoption analysis.  
D. Baines et al.                                                                                                                                                                                                                                  
Social Science & Medicine 276 (2021) 113830
4
Fig. 2. Probability distribution of rate of return (r).  
Fig. 3. Graphical representation of expected value (μ) and risk (σ).  
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suggests, r is not the only variable that healthcare purchasers should 
consider. Just like financial investments, differing rates of return possess 
different risks. For instance, the options that offer the largest payoffs 
often have the greatest dispersion of observed rewards. 
The challenge is thus (following Markowitz) to create an optimal 
portfolio as in Equation (1), which achieves an acceptable baseline ex-
pected rate of return on an asset with minimal variance (for the purpose 
of this research, an “asset” in the healthcare sense of the optimal port-
folio is any health intervention, such as a new technology, drug, or 
policy). In the health system, a portfolio of chosen health interventions 
is “mean-uncertainty efficient” if it maximizes the expected value of the 
rate of return of the portfolio for a given uncertainty (i.e., portfolio 
variance) or, equivalently, minimizes the uncertainty for a given port-
folio expected rate of return. 
A difficulty in this model is that the expected value of each asset and 
the variance–covariance matrix of the portfolio are assumed to be 
known. However, following Salter’s (Salter, 1960) description of dy-
namic technical change, it is unlikely that these parameters will be 
known until an intervention is used. This is the case for three main 
reasons. First, pre-adoption evidence is usually based upon clinical trial 
or modelling results that are isolated from the continual economic dis-
turbances experienced in the real world. Next, manufacturers may 
suppress unfavorable evidence during HTA submissions. Finally, health 
systems are dynamic and reactive, so technical processes of production 
and factor prices will continuously alter in unpredictable ways. 
4. From portfolios to frontiers 
Fig. 3a shows the first step in our application of Markowitz’s 
approach to portfolio decision making in health systems, which involves 
plotting all available interventions in an expected value (μ) - risk (σ) 
space. If we compare points one and two, the former intervention has the 
same expected return as the latter, with both having an almost zero 
yield. However, the former intervention has a significantly lower 
dispersion of expected returns. In contrast to point two, points three and 
four have identical levels of uncertainty but higher expected returns. 
Therefore, points three and four are preferred to point two because they 
perform better. If we continue applying this logic, the diagram shows 
that point four is preferred to point five because they have identical 
returns, but the former has lower uncertainty. Next, point six is inter-
esting as it has the largest return and uncertainty by far. Given its 
outlying position, a comparator is not obvious, and we need to employ 
an appropriate decision rule to determine whether its expected returns 
are worth the large variability in its results. As a means of dealing with 
such situations, the next stage in the presentation of our PFA is showing 
how appropriate decision rules may be applied to portfolio choice. 
4.1. Floor and ceiling constraints 
To generate more realistic models, one can consider additional 
constraints, among which the floor and ceiling constraints are relatively 
common in the literature. The floor and ceiling constraints define lower 
and upper levels per intervention investment representing health system 
decision makers’ preferences. In our PFA, the floor constraint is an 
“economic” constraint that we can call “economic floor”, defined by the 
lowest acceptable level of expected value. Most HTA processes reject 
interventions with low expected economic returns, so not all in-
terventions assessed are subsequently adopted. In our framework, we 
follow this approach and suggest that health system decision makers 
should consider excluding the least cost-effective interventions from 
their portfolios. In making this recommendation, we are assuming per-
fect divisibility and constant returns to scale. If these assumptions are 
relaxed, it may be efficient to include the least cost-effective in-
terventions in a portfolio depending upon their size and their (average) 
rate of return (Gafni et al., 2013). However, we do not explore this 
option here. 
As Fig. 3b shows, we can apply a minimum threshold to our hypo-
thetical data, which sets a floor for economic acceptability. In our 
example, the chosen floor leads to the rejection of the points in the 
shaded areas I and III. As well as determining which interventions to 
exclude, the floor also helps set (what we call) the minimum expected 
return (MER), which occurs where the floor intersects the horizontal 
axis. This position is chosen because it is located where the floor co-
incides with the point representing zero uncertainty. Consequently, 
MER is an important reference point because all other acceptable points 
have either greater returns, higher levels of uncertainty, or a combina-
tion of both. 
The ceiling constraint is an “uncertainty” constraint that we call the 
“uncertainty ceiling”, defined as the maximum acceptable level of risk. 
As well as avoiding treatments with low expected returns, health sys-
tems may consider some interventions too unstable in their expected 
results to be used routinely (outside of experimental or emergency 
cases). In response, our framework contains an uncertainty ceiling above 
which decision makers are unwilling to fund treatments. As Fig. 3b 
shows, any intervention in areas II or III are considered too uncertain for 
routine use because they lie above the ceiling. Therefore, interventions 
in these areas should be excluded from purchasing plans. Finally, if we 
combine the “uncertainty ceiling” with the “economic floor”, Fig. 3b 
shows which interventions should and should not be considered for 
purchasing. In practice, the uncertainty ceiling will not be a fixed value 
but will depend on the opportunity cost of choosing one intervention 
over another (Palmer and Raftery, 1999). Consequently, PFA raises 
many new questions and calls for a new, pragmatic approach to HTA. 
For instance, for smaller investments, would a decision-maker be willing 
to accept a higher level of uncertainty than she would accept for larger 
investments? Moreover, new means of quantifying benefits forgone are 
needed for PFA and other forms of health economics analysis (Sculpher 
et al., 2017). 
4.2. PFA diagram 
Fig. 3c shows the interventions available for evaluation after inef-
fective and risky treatments have been removed (i.e., any interventions 
in areas I, II, and III of Fig. 3b are not considered). We can now see points 
in the expected value (μ) - risk (σ) space that have different combina-
tions of efficiency and uncertainty. Points with higher returns or lower 
levels of uncertainty are always preferred. Consequently, we draw an 
efficiency frontier that links the most preferred points, which is shown 
by the series of straight lines connecting A, B, C, D, and E. The area to the 
north-west of the frontier is unattainable because interventions do not 
exist in this space. This is identified by the shading outside of the 
frontier. In contrast, the points shown within the frontier are attainable. 
However, they have lower expected returns and/or higher levels of 
uncertainty than those at the frontier. 
4.3. Examples of application of the basic model 
Fig. 3d shows our hypothetical data, with points A, B, C, and D 
representing alternative interventions for treating the same condition, 
with the four interventions lying within the portfolio frontier. Following 
a scientific breakthrough, a new intervention is launched that pushes the 
frontier outwards. This is a technological shock because its combination 
of expected return and uncertainty far outperforms those offered by the 
existing interventions. The points represented in Fig. 3d do not portray 
the dynamic nature of continually disturbed health systems. In contrast, 
Fig. 3e shows how the five interventions evolve from their baseline 
positions at A0, B0, C0, D0, and N0 to their locations at A1, B1, C1, D0, and 
N1. First, the launch of the new intervention stimulates the manufac-
turers of A to make their intervention more cost effective and less var-
iable in its expected return. As a result, A moves to just inside the dotted 
line and rests at A1, which coincides with the frontier attainable before 
the new treatment was launched. Similarly, changes in technical 
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processes make B1 more cost effective and less uncertain than B0, 
pushing the intervention nearer the previous frontier. 
Although A1 and B1 are superior to A0 and B0, they are not preferable 
to N0. While this implies that the new intervention should be chosen, 
data collected during the first time period suggest results from the new 
intervention are more uncertain than expected. At the end of the first 
time period, N has failed to push the portfolio frontier outwards, the 
observed technology shock is not sustained, and the intervention settles 
at N1. Even though the three interventions hold different locations in the 
E, U space, they are all on or close to the frontier. Therefore, A and B may 
be near equivalents to N. In such situations, health systems decision 
makers must weigh the pros and cons of their available portfolio of in-
terventions. For instance, they may choose A over B and N because the 
former offers the lowest variability in results, even if this choice results 
in efficiency levels being lower than possible with the latter two options. 
Conversely, in more time-constrained situations, as with the COVID-19 
outbreak, efficiency levels rather than variability may be the metric of 
success. 
As Fig. 3e shows, HTA decisions made at launch may not reflect the 
changing dynamic of continual disturbance frequently observed within 
health systems. For instance, new interventions may fail to perform as 
well as expected, stimulate improvements in competitor treatments, and 
shift from being dominant at launch to being equivalent during use. In 
drawing these conclusions, we must also acknowledge that existing 
technologies do not always respond positively to the launch of seem-
ingly superior alternatives. For instance, C improves in cost effectiveness 
compared with C1, but this is only achieved by reformulating the 
product in a way that produces greater variability in its results. As 
another comparison, intervention D remains stuck at D0 because it 
cannot evolve. In sum, C and D would not be interventions of choice 
when N is launched, and continuous economic evaluation confirms that 
the choice not to use them remains correct. 
Fig. 3f shows the effects of continual small reactions and modifica-
tions. The four interventions shown are stimulated by evolving technical 
processes and, crucially, the evolution of factor prices exogenous to the 
health sector. For instance, A and C improve their rate of return during 
period one without increasing the uncertainty of their results. In 
contrast, intervention B only achieves an improvement in its expected 
return by adopting methods that increase the variability of its outcomes, 
while D experiences a drop. At points A1, B1, C1, and D1, the in-
terventions are located differently to their original positions. Sensing the 
ability to catch up, the manufacturers of intervention B modulate their 
production processes to move their product nearer to the position of A1. 
This move affects the relative position of C, the producers of which try to 
gain ground by lowering its price, thus ending up at C2. Sensing a 
shifting market dynamic, the makers of A push their product to be more 
cost effective, moving from A1 to A2. In doing so, they outperform their 
existing competitors, shift the portfolio frontier outwards, and create 
gains by accepting more uncertainty in their results. At the other end of 
the spectrum, intervention D performs increasingly worse over time, 
with the consequence that it should probably be excluded from future 
purchasing plans when it reaches D2. 
4.4. Decision makers 
Fig. 4 presents a more sophisticated form of our PFA that again in-
cludes the MER point in the diagram. The minimum expected return is 
located where any asset would give zero variation in its rate of return 
and offer the minimum return expected by health system purchasers. 
This is an important benchmark because MER is a corner solution that 
indicates the minimum return, zero uncertainty position acceptable to 
health systems purchasers. MER can be used as an anchor point when 
forming a new efficiency frontier, which is tangent with the most effi-
cient intervention available, shown by A. This frontier differs from other 
efficiency frontiers because its position is partly determined by decision 
makers themselves, whereas the previous frontiers were located solely 
by the position of the observed interventions. In response, we label this 
new frontier the “decision-makers’ frontier” (DMF). Given their ability 
to set MER via modulations in the economy, DMF is a frontier that health 
systems can control, subject to the location of existing technologies in 
the analytic space. 
The DMF is an economic frontier that may rarely be observed in 
practice but may be useful in shaping abstract models of decision 
making. Its key features may be interpreted as follows. First, the fron-
tier’s connection with the vertical axis represents an intervention with 
no uncertainty in its expected returns. No variability in results should 
always be preferred to variability, which makes the MER an important 
guide to optimal choice. Next, the tangency of DMF with point A rep-
resents an uncertain return that is equivalent to MER, which gives a 
higher pay-off to compensate for greater variability. In other words, the 
slope of the DMF is equivalent to the rate of exchange between expected 
returns and uncertainty that would be observed if health systems 
operated at their DMF frontier. Finally, all points on the DMF (except A 
and the MER) are hypothetical and represent the most efficient combi-
nations of μ and σ that could feasibly exist, given MER and A. The DMF 
acts as a frontier against which to judge the relative worth of in-
terventions available to health systems purchasers. 
PFA has practical applications for health systems decision-makers. 
Currently, HTA information is generated pre-launch usually by 
agencies outside the management structures of the organizations that 
purchase and supply interventions to patients. Given its structure, PFA 
allows decision-makers to set floor and ceiling values for effectiveness 
and risk. Control is also given over the MER and the decision-makers’ 
frontier. As PFA evaluates risk and returns during the dynamic process of 
use, it suggests that bodies running the day-to-day operations of health 
systems should be in charge of implementing this method in practice. 
For instance, PFA should be operated by NHS England rather than NICE 
in the UK, which would give the former greater control of efficiencies, 
Fig. 4. Decision-makers’ frontier (DMF) with expected value (μ) and risk (σ).  
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especially in relation to high-cost drugs (Baines, 2018b). To enable such 
applications, researchers need to identify suitable forms of RWD useable 
in different health systems that facilitates the successful implementation 
of PFA. 
The implementation of PFA will present new challenges for re-
searchers and health systems funders. First, there will be the issue of 
identifying which interventions best suit this approach. For instance, 
products that are not dominant or dominated in the cost-effectiveness 
plane may be suitable candidates for post launch analysis. However, 
cost-effective interventions may also require continuous evaluation 
because their competitors may change methods of delivery and prices in 
order to compete with their new rivals. Alternatively, areas of medicine 
where innovative products are rare, but healthcare professionals make 
constant, but small improvements in their performance may be good 
areas for implementing PFA. In the short term, decision-makers may 
choose to focus on specific groups of interventions as a means of building 
experiencing of HTA using a portfolio approach. For instance, attention 
will need to be paid to how information about expected values and risk 
going beyond using these “average” values and to explore the role of 
opportunity cost in portfolios. In pre-launch HTA, the recommendation 
of adoption usually involves strict criteria for use and assumptions about 
cost effectiveness thresholds that are rarely acknowledged once adop-
tion occurs. With PFA, the way the product is used in conjunction with 
decision-makers economic criteria will constantly inform choices about 
which interventions to use. Therefore, PFA makes HTA a “living” process 
that health system decision-makers can continuously control. 
Finally, the possible use of Value of Information (VoI) studies in the 
PFA is useful to discuss (Claxton and Sculpher, 2006). VoI analysis 
provides an analytic framework for establishing the value of acquiring 
additional information to inform a decision problem. If decision-maker 
aim to maximise health outcomes subject to a budget constraint, then 
the choice to adopt or reimburse an alternative should be based on ex-
pected cost, expected outcomes and the cost effectiveness threshold. 
With perfect information, decision-makers can select interventions that 
maximise the net benefits of adoption for a particular health threshold. 
The expected value of perfect information is simply the difference be-
tween the expected value of decisions made with perfect information 
and the decisions made on the basis of existing evidence. When further 
research appears to be worthwhile, the approach indicates where evi-
dence about particular parameters will be most valuable and suggests 
the type of research design which might be most important. Therefore, 
we suggest that the possibility of using VoI studies to support PFA should 
be further explored. 
5. Conclusion 
In suggesting the use of PFA, we are aware of the robustness of the 
current HTA methods employed worldwide, so full justification for 
preferring PFA is required. First, we believe our novel approach could 
supplement existing health economics and HTA methods, especially 
given the challenges of the COVID-19 crisis. Even when comprehensive 
modelling studies are undertaken, mainstream evaluations often fail to 
capture the dynamics of the evolutionary economic systems determining 
health systems outcomes. Currently, most formal assessments of health 
economics evidence are performed outside of the health systems they 
are designed to serve, usually by independent HTA bodies. As a result, 
their recommendations are usually based upon once-over evaluations, 
which may have diminishing validity over time as their findings are 
challenged by continual disturbances slowly operating within health 
systems. 
As noted, techniques of production change over time as technical 
knowledge and factor prices alter (Salter, 1960). In health systems, these 
drivers generate continuous streams of new working methods. For 
instance, healthcare professionals will continually learn how to generate 
incremental benefits from existing techniques until an unexpected 
technology shock disrupts the technical and economic dynamics of their 
production processes. In most instances, slow but continuous change 
will generate the most significant economic gains. Unfortunately, cur-
rent methods rarely focus on the technical changes made by market 
incumbents in response to new interventions and modulating factor 
prices. 
The operation of the complex economic processes that shape health 
systems outcomes is rarely observed for economic evaluations. As once- 
over, pre-adoption evaluations cannot capture the cumulative benefits 
of small improvements in production methods, PFA could be a useful 
addition to current health economics and HTA methods. In proposing 
PFA as a form of post-adoption analysis, we wish to refocus attention on 
analyzing the effects of the underlying dynamics that drive health sys-
tems. Indeed, measuring the impact of new and existing technologies 
during their use could be informative because, often, the full benefits of 
innovation emerge over time because of continued learning from use. 
Only with the gift of complete foresight can pre-adoption evaluations 
truly predict the economic consequences of allowing new technologies 
to enter the market. Given that we live in a second-best world, post- 
adoption methods such as PFA could become useful additions to exist-
ing approaches to health systems economics and HTA. 
PFA may be a useful tool for post-adoption decision making in health 
systems in five main ways: (1) the PFA diagram represents combinations 
of μ and σ that can be attained with available interventions, (2) the 
approach can help analysts separate efficient from inefficient in-
terventions, (3) the framework could help decision makers select the 
combinations of μ and σ that best suit the needs of their health systems, 
(4) the approach can help determine which interventions are the most 
suitable for particular patient groups, and (5) its ability to use real-world 
data means that PFA can reflect the continual disturbances that shape 
the economics of healthcare provision. 
Widespread adoption of PFA has the potential to affect the main-
stream working procedures of HTA in the following ways. First, the use 
of PFA implies that only potentially “dominant” technologies should be 
subject to full-scale pre-adoption assessments. Consequently, in-
terventions that are likely to be equivocal in their cost effectiveness 
should be evaluated in use and withdrawn from purchasing portfolios if 
they perform poorly. Next, if HTA bodies only perform pre-adoption 
assessments on technologies that shock existing production processes, 
the job of evaluating all other interventions could be a regular activity of 
health systems themselves. Used in a feedback loop, the methodology 
could be employed by health systems in all countries (regardless of their 
structure and public/private mix) to improve efficiency and reduce 
uncertainty. Moreover, as it does not require inputs from a formal HTA 
agency, PFA could be performed by analysts working within (or for) 
health systems themselves, who could employ local management 
structures to encourage providers to improve the results being moni-
tored. Finally, new sources of real-world data and methods of analytics 
will be required to operationalize PFA. Although this will be costly, cash- 
limited health systems have little option but to actively manage their 
growing portfolios of interventions if they wish to successfully stay 
within budget limits. Therefore, with its dynamic nature, PFA may be an 
appropriate support tool for health systems decision makers concerned 
with the returns and risks of their spending. 
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